Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
Sponsor: Organon and Co
Listed as NCT05032859, this PHASE3 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Organon and Co, it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Mar 2023 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Organon and Co
For direct contact, visit the study record on ClinicalTrials.gov .